The US spends extra on well being care than some other nation, pouring in a whole lot of billions of {dollars} annually on analysis, sprawling authorities programmes, and high-profile initiatives. However what does it have to indicate for this large funding? Skyrocketing prices, deep inequalities in entry, and well being outcomes that lag many developed nations. Each its medical and analysis techniques have grown bloated and inefficient, more and more disconnected from the actual wants of sufferers.
The US Most cancers Moonshot is a textbook instance of this dysfunction. Launched by President Barack Obama in 2016, with Vice President Joe Biden championing it, the programme promised to remodel most cancers care — accelerating analysis, delivering new therapies, and saving lives. Touted as a daring mission to realize 10 years of progress in simply 5, it secured over $2 billion in funding. Biden made it a private campaign, reviving and increasing the initiative throughout his presidency. But almost a decade later, the outcomes are meagre. Bulletins have been made and papers revealed, however little got here of this.
In sharp distinction, India is demonstrating what true well being care innovation seems to be like — with a fraction of the sources. Karkinos Healthcare, a personal enterprise I’ve mentored and suggested, got down to revolutionise most cancers care with simply $100 million in investor funding — a sum that may barely register in US well being care budgets. And in simply 4 years — lower than the Moonshot’s unique timeline — Karkinos has constructed a nationwide most cancers care community that delivers measurable, life-saving outcomes at a scale the US programme may solely dream of.
Immediately, Karkinos operates 80 centres throughout 12 states, having screened greater than 3 million folks and identified over 60,000 most cancers sufferers. Of those, 35,000 are from distant villages and small cities that beforehand had no entry to most cancers care in any respect. 1000’s of lives have already been saved. Not like the US moonshot, this isn’t PR spin — it’s actual progress, delivered with precision and affect.
Karkinos’s success is constructed on execution and sensible partnerships. It collaborates with hospitals and clinics to supply screenings and diagnostics near residence, escalating advanced instances to higher-level centres solely when wanted. Its digital spine ensures each affected person’s journey is tracked and managed, closing gaps that usually plague most cancers care in low-resource settings. The complete expertise is mapped — like an Uber for most cancers care — with every part digitised and tightly coordinated. Tumour boards overview every affected person’s remedy plan to make sure a second opinion is all the time a part of the method. Charges are pre-negotiated and a fraction of what insurance coverage firms or sufferers would usually pay. The system is quick, environment friendly, and totally patient-focused.
The journey was removed from simple. At one level, Karkinos was in deep trouble — grappling with logistical challenges, funding shortfalls, and scepticism. Its very survival was at stake. However via willpower, problem-solving, and tight execution, the group turned issues round and achieved what the US couldn’t.
In the meantime, the US Most cancers Moonshot — regardless of its large price range and high-profile guarantees — delivered little greater than press releases and committee conferences. I noticed this complacency firsthand via my interactions with its management, together with a White Home assembly and in depth follow-up discussions. My objective was to advocate for collaboration with India, highlighting the expertise Karkinos had constructed and the treasure trove of medical knowledge it had amassed — supplied freely as a part of a groundbreaking partnership. However as a substitute of seizing this opportunity to leap ahead, the Moonshot group reverted to its typical routine. It handed out grants to favoured researchers who churned out tutorial papers with little sensible affect, and endlessly scheduled conferences with different authorities bureaucrats, disregarding India’s capabilities with thinly veiled condescension, as if it couldn’t probably have constructed world-class expertise.
The sense of urgency was all for present. Sufferers continued to endure — and die — whereas the federal government’s equipment crawled alongside at its typical tempo. The Moonshot’s failure isn’t distinctive; it displays a deeper subject. The US well being care system is hooked on funding tutorial analysis and pilot initiatives that not often scale. There’s a reluctance to deal with the exhausting, unglamorous work of delivering confirmed options at scale. The outcome? A system lengthy on discovery however painfully brief on significant affect.
Karkinos presents a distinct path, fixing real-world issues now, at scale, and utilizing current applied sciences. It’s a mannequin pushed by necessity and ingenuity — and it’s working.
With Reliance Industries buying Karkinos and Mukesh Ambani compassionately backing its growth, the corporate is ready to scale quickly. Reliance brings the capital, attain, and operational experience to take the Karkinos mannequin throughout India — and ultimately to different international locations. What started as a daring well being care startup is quick turning into a blueprint to ship most cancers care — and healthcare extra broadly — successfully and equitably.
America spends almost 18% of its GDP — over $4 trillion yearly — on well being care. But, it delivers poor outcomes. Much more troubling is how a lot of that funding is tied up in analysis that not often interprets into real-world enhancements. India, too, faces calls from worldwide specialists to pour extra public cash into analysis. However quite than copying the US mannequin of analysis for its personal sake, India’s policymakers ought to deal with what’s already working — government-industry partnerships constructed for execution, scale, and outcomes.
The world doesn’t want extra Moonshots that fizzle out; it wants extra Karkinos-style revolutions that ship.
Vivek Wadhwa is CEO, Vionix Biosciences. The views expressed are private
